RPL22P21

Across TCGA pan-cancer cohorts, RPL22P21 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RPL22P21’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RPL22P21 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL22P21 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, STAD, and KIRC are the cancer types where RPL22P21 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL22P21 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.076	<.001	6	view →
STAD	Male	IV	+0.325	<.001	4	view →
KIRC	Female	All	+0.069	.005	3	view →
BRCA	All	III,IV	−0.129	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RPL22P21–THCA

Open the THCA breakdown →